Open Access Highly Accessed Case report

First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin

Ayaka Tsukimori12, Itaru Nakamura1*, Sakiko Okamura3, Akihiro Sato12, Shinji Fukushima1, Yasutaka Mizuno1, Tetsuo Yamaguchi4 and Tetsuya Matsumoto2

Author Affiliations

1 Department of Infection Control and Prevention, Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan

2 Department of Microbiology, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-8402, Japan

3 Department of Medical Treatment for Health Scientific Research, Bunkyo Gakuin University Graduate School, 1-19-1 Mukougaoka, Bunkyo-ku, Tokyo 113-8668, Japan

4 Department of Microbiology and Infectious Diseases, Toho University Faculty of Medicine, 5-21-16 Omorinishi, Oota-ku, Tokyo 143-8540, Japan

For all author emails, please log on.

BMC Infectious Diseases 2014, 14:459  doi:10.1186/1471-2334-14-459

Published: 23 August 2014

Abstract

Background

Sequence type 72 methicillin-resistant Staphylococcus aureus (MRSA) SCCmec type IV (ST72-MRSA-IV) is the most common community-acquired MRSA clone in Korea. Resistance to daptomycin or vancomycin among community-acquired MRSA clones is not well described in the literature. We herein report the first case of vancomycin-intermediate, daptomycin-nonsusceptible ST72-MRSA-IV.

Case presentation

A 45-year-old Japanese man underwent aortic arch prosthesis implantation for treatment of a dissecting aortic aneurysm. Fourteen months later, he developed a prosthetic graft infection of the aortic arch and an anterior mediastinal abscess caused by ST72-MRSA-IV. First-line treatment with vancomycin and rifampicin failed, and daptomycin was thus administered. After several days, the treatment was changed to linezolid because of the re-emergence of fever. The patient’s condition resolved and no recurrence or other problems were seen for 1 year post-treatment. The infectious agent was definitively identified as vancomycin-intermediate, daptomycin-nonsusceptible, rifampicin-resistant ST72-MRSA-IV based on culture results and minimum inhibitory concentration testing.

Conclusion

This case report illustrates the importance of fully understanding the changing epidemiology of infectious agents and the risk factors for the development of antibiotic resistance. Such information will help to minimize the emergence and spread of antibiotic-resistant strains. This report concerns one particular bacterial strain; however, the basic concepts involved in this case translate to all infectious disease fields.

Keywords:
MRSA; Daptomycin; Sequence type 72-MRSA-SCCmec type IV (ST72-MRSA-IV); Daptomycin nonsusceptibility; Vancomycin-intermediate resistance; Rifampicin resistance; High-dose daptomycin